

OMICS Journals are welcoming Submissions

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way.

OMICS Journals are poised in excellence by publishing high quality research. OMICS International follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website:


<http://omicsonline.org/Submitmanuscript.php>



ISSN-2155-9929

Journal of Molecular Biomarkers & Diagnosis

Open Access



Priyanka Trivedi

Postdoctoral Research Fellow

Dr. Sandra Gendler's lab


Biochemistry and Molecular Biology

Johnson Medical Research Building

Mayo Clinic


13400 East Shea Boulevard

Scottsdale, AZ 85259




Current Research area

- ❖ Vaccine-based cancer immunotherapy
 - Role of MUC1, a mucin that is over-expressed and aberrantly glycosylated in various types of cancer, in tumor progression, metastasis and modulation of the immune system
 - Characterization of MUC1 as a tumor vaccine




Why MUC1?

- MUC1 is a heavily glycosylated transmembrane mucin that is expressed on the apical surface of glandular epithelial cells at low levels and at very high levels following transformation to cancerous cells
- Various types of cancer exhibit a striking over-expression and aberrant immature truncated O-glycosylation of MUC1
- The glycopeptide epitopes of aberrantly glycosylated MUC1 are susceptible to recognition by cytotoxic T lymphocytes and can also be bound by antibodies to mediate antibody-dependent cell-mediated cytotoxicity
- Earlier it was proved in our lab that immunization of mice with the glycosylated tripartite vaccine, composed of an immunoadjuvant (TLR2 agonist), a peptide T helper epitope and an aberrantly glycosylated MUC1 peptide, was able to reduce the tumor burden in mice



Ongoing research..

- Determination of the role of MUC1 in cell adhesion, tumor progression, metastasis and modulation of the immune system.
- Characterization of tumor antigens as tumor vaccines.
- Elucidating the molecular and genetic mechanisms involved in the accumulation of truncated O-glycans in most of the epithelial cancer cells.
- Deciphering the role of cosmc, a chaperone required for O-glycan elongation, in decreasing tumor progression and metastasis by modulating the immune system.



My research interest also includes:

- Elucidation of the molecular mechanisms involved in the pathogenesis of ulcerative colitis-associated local damage and extra-intestinal manifestations as well as colitis-associated colon carcinogenesis
- We provided the mechanistic association between colitis-induced local as well as global damage, *viz.*, hepatic and systemic damage and elucidated the role of gut bacteria therein
- We also studied the role of autophagy and Nrf2 signaling pathways in the progression of colitis-associated colon carcinogenesis



- Pre-clinical toxicology (genotoxicity, carcinogenesis, hepatotoxicity, cardiotoxicity, nephrotoxicity, germ cell toxicity, reproductive toxicology)
- Pre-clinical drug development
- Molecular biology
- Molecular toxicology
- Regulatory toxicology
- Risk assessment
- Endocrine disruption

Molecular Biomarkers & Diagnosis Related Journals

- Advancements in Genetic Engineering
- Journal of Molecular and Genetic Medicine



For Upcoming Conferences

➤ <http://www.conferenceseries.com/>



OMICS Group Open Access Membership

OMICS publishing Group Open Access Membership enables academic and research institutions, funders and corporations to actively encourage open access in scholarly communication and the dissemination of research published by their authors.

For more details and benefits, click on the link below:

<http://omicsonline.org/membership.php>

